novel agents to improve outcomes for patients with multiple myeloma in the salvage setting
Published 7 months ago • 91 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
1:18
how will novel agents be sequenced for patients with multiple myeloma?
-
3:24
novel agents for the management of r/r myeloma
-
2:54
how novel agents & individualized treatment approaches are improving outcomes in patients with aml
-
1:18
targeted therapies in r/r myeloma: novel approaches being explored
-
1:35
the value of ctcs and cfdna as novel biomarkers in multiple myeloma
-
2:09
integrating novel agents into the treatment of multiple myeloma
-
1:17
frailty-adapted therapy in myeloma: session takeaways
-
51:24
‘standing on the shoulders of the giants’ with prof. giampaolo merlini
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
2:13
novel agents in development for multiple myeloma: celmods, antibody-drug conjugates, and peptides
-
1:15
bringing novel agents to the frontline setting in myeloma
-
3:54
an insight into how novel agents are influencing survival outcomes in patients with mf
-
1:20
improving patient outcomes in ctcl: clinical collaboration and novel agents
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
1:01
advancements in cml: improving treatment-free remission and novel agents
-
2:12
using a novel machine learning model to analyze and predict the outcomes of patients with ndmm
-
1:34
promising novel agents for relapsed/refractory multiple myeloma
-
3:22
advances and unanswered questions in aml: novel agents, mrd assessment, and immunotherapy
-
5:19
the current treatment landscape for multiple myeloma and trials investigating novel combinations
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
1:36
the use of outpatient cilta-cel in the treatment of multiple myeloma